Proposed Topic (Most preferred): :
Clinical Safety and Quality Service II (Projects aiming to enhance clinical safety and outcomes, clinical governance / risk management)
Authors (including presenting author) :
Yu HL
Affiliation :
Pharmacy, Castle Peak Hospital
Introduction :
Both lurasidone and aripiprazole are atypical antipsychotics that demonstrated limited adverse events, including metabolic side effects, in their clinical trials. However, there was a lack of head-to-head comparison of newer atypical antipsychotics, including a comparison of lurasidone and aripiprazole.
Objectives :
It aims to compare the tolerability profile of lurasidone and aripiprazole by discontinuation proportion due to treatment-emergent adverse events (TEAEs) and the number of patients who reported TEAEs. It also aims to compare the hospitalization rate of the patients using lurasidone and aripiprazole.
Methodology :
The clinical information obtained from the electronic patient record of 66 patients using lurasidone and 157 patients using aripiprazole was reviewed in the retrospective study. Patient demographics, the proportion of patients experiencing TEAEs, discontinuation proportion, description of TEAEs, all-cause and mental health-related admission and length of stay were recorded and compared statistically.
Result & Outcome :
24 patients using lurasidone and 54 patients using aripiprazole reported TEAE through electronic patient record during follow-up after adding treatment or dose titration, but no statistically significant difference was found (36.4% vs 34.4%, adjusted OR= 0.949 (0.445-2.026)). Also, no significant difference was found between the proportion of discontinuation due to TEAE (21.2% vs 18.5%, adjusted OR= 1.052 (0.418-2.650)). There was no statistically significant difference between the lurasidone and aripiprazole groups regarding the number of admission episodes and length of stay for all-cause and mental health-related hospitalization.
